Twist Bioscience Shareholders Back Directors and Governance Items

Twist Bioscience ( (TWST) ) has issued an announcement.

At its 2026 Annual Meeting of Stockholders, Twist Bioscience Corporation reported that approximately 91.81% of eligible shares were represented in person or by proxy, reflecting strong shareholder engagement. Stockholders elected three Class II directors—Keith Crandell, Jan Johannessen, and Trynka Shineman Blake—to three-year terms, approved on an advisory basis the compensation of the company’s named executive officers, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, collectively signaling continued investor support for the company’s leadership, governance practices, and financial oversight.

The most recent analyst rating on (TWST) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on Twist Bioscience stock, see the TWST Stock Forecast page.

Spark’s Take on TWST Stock

According to Spark, TipRanks’ AI Analyst, TWST is a Neutral.

Score is held back primarily by weak financial performance driven by ongoing losses and negative operating/free cash flow. Offsetting factors include strong technical momentum and a constructive earnings outlook with raised FY2026 guidance and continued margin expansion, while valuation remains challenged due to lack of profitability and no dividend support.

To see Spark’s full report on TWST stock, click here.

More about Twist Bioscience

Twist Bioscience Corporation operates in the biotechnology sector, specializing in synthetic DNA manufacturing and related genomic tools that serve pharmaceutical, industrial, and academic customers focused on drug discovery, diagnostics, and other life science applications.

Average Trading Volume: 1,495,739

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2.95B

For a thorough assessment of TWST stock, go to TipRanks’ Stock Analysis page.